ALNY – Alnylam Pharmaceuticals, Inc.
ALNY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.59
Margin Of Safety %
-1
Put/Call OI Ratio
0.39
EPS Next Q Diff
0.47
EPS Last/This Y
7.14
EPS This/Next Y
4.44
Price
297.44
Target Price
441.58
Analyst Recom
1.71
Performance Q
-9.69
Upside
-50.5%
Beta
0.29
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-24 | ALNY | 305.61 | 0.42 | 0.20 | 21585 |
| 2026-04-27 | ALNY | 308.71 | 0.42 | 0.23 | 21805 |
| 2026-04-28 | ALNY | 302.13 | 0.41 | 0.83 | 21643 |
| 2026-04-29 | ALNY | 301.46 | 0.40 | 0.46 | 21672 |
| 2026-04-30 | ALNY | 309.28 | 0.41 | 0.16 | 22683 |
| 2026-05-01 | ALNY | 296.06 | 0.41 | 1.71 | 22669 |
| 2026-05-04 | ALNY | 298.07 | 0.42 | 0.45 | 23390 |
| 2026-05-05 | ALNY | 301.08 | 0.41 | 0.16 | 23810 |
| 2026-05-06 | ALNY | 303.01 | 0.40 | 0.42 | 24363 |
| 2026-05-07 | ALNY | 295.84 | 0.41 | 0.73 | 24364 |
| 2026-05-08 | ALNY | 294.81 | 0.40 | 0.39 | 24492 |
| 2026-05-11 | ALNY | 284.66 | 0.40 | 0.52 | 24563 |
| 2026-05-12 | ALNY | 292.02 | 0.40 | 1.32 | 24931 |
| 2026-05-13 | ALNY | 291.71 | 0.41 | 0.18 | 25191 |
| 2026-05-14 | ALNY | 293.38 | 0.41 | 0.61 | 25072 |
| 2026-05-15 | ALNY | 286.85 | 0.40 | 1.17 | 24972 |
| 2026-05-18 | ALNY | 286.28 | 0.40 | 0.43 | 22154 |
| 2026-05-19 | ALNY | 294.4 | 0.39 | 0.07 | 22169 |
| 2026-05-20 | ALNY | 298.44 | 0.38 | 1.16 | 22549 |
| 2026-05-21 | ALNY | 300.58 | 0.39 | 0.32 | 22740 |
| 2026-05-22 | ALNY | 297.36 | 0.39 | 0.50 | 22838 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-24 | ALNY | 305.65 | 14941.7 | 747.5 | 9.21 |
| 2026-04-27 | ALNY | 308.65 | 14941.7 | 798.6 | 9.21 |
| 2026-04-28 | ALNY | 302.14 | 14808.3 | 755.0 | 9.23 |
| 2026-04-30 | ALNY | 309.34 | 14808.3 | 822.6 | 9.23 |
| 2026-05-01 | ALNY | 296.11 | 14808.3 | 726.5 | 9.23 |
| 2026-05-04 | ALNY | 298.02 | 544.0 | 558.4 | 7.90 |
| 2026-05-05 | ALNY | 301.10 | 546.4 | 564.4 | 9.26 |
| 2026-05-06 | ALNY | 303.01 | 546.4 | 558.2 | 9.26 |
| 2026-05-07 | ALNY | 295.90 | 546.4 | 531.5 | 9.27 |
| 2026-05-08 | ALNY | 295.01 | 545.6 | 560.8 | 9.33 |
| 2026-05-11 | ALNY | 284.74 | 545.6 | 514.9 | 9.33 |
| 2026-05-12 | ALNY | 292.17 | 545.6 | 602.3 | 9.33 |
| 2026-05-13 | ALNY | 291.91 | 545.6 | 564.6 | 9.33 |
| 2026-05-14 | ALNY | 293.33 | 545.6 | 574.4 | 9.33 |
| 2026-05-15 | ALNY | 286.92 | 545.6 | 533.2 | 9.33 |
| 2026-05-18 | ALNY | 286.38 | 545.6 | 562.2 | 9.33 |
| 2026-05-19 | ALNY | 294.38 | 545.6 | 605.5 | 9.33 |
| 2026-05-20 | ALNY | 298.39 | 545.6 | 585.2 | 9.33 |
| 2026-05-21 | ALNY | 300.58 | 545.6 | 575.3 | 9.33 |
| 2026-05-22 | ALNY | 297.44 | 576.7 | 550.5 | 9.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-24 | ALNY | -11.01 | -0.87 | 3.82 |
| 2026-04-27 | ALNY | -11.01 | -0.92 | 3.80 |
| 2026-04-28 | ALNY | -11.01 | -0.92 | 3.80 |
| 2026-04-29 | ALNY | -11.01 | -0.92 | 3.80 |
| 2026-04-30 | ALNY | -11.01 | -0.92 | 3.80 |
| 2026-05-01 | ALNY | -11.01 | -0.92 | 3.80 |
| 2026-05-04 | ALNY | -11.01 | -1.04 | 3.80 |
| 2026-05-05 | ALNY | -11.01 | -1.04 | 3.80 |
| 2026-05-06 | ALNY | -11.01 | -1.04 | 3.80 |
| 2026-05-07 | ALNY | -11.01 | -1.04 | 3.80 |
| 2026-05-08 | ALNY | -11.01 | -1.04 | 3.80 |
| 2026-05-11 | ALNY | -11.01 | -1.53 | 3.80 |
| 2026-05-12 | ALNY | -11.01 | -1.53 | 3.60 |
| 2026-05-13 | ALNY | -11.01 | -1.53 | 3.60 |
| 2026-05-14 | ALNY | -11.01 | -1.53 | 3.60 |
| 2026-05-15 | ALNY | -8.75 | -1.53 | 3.60 |
| 2026-05-18 | ALNY | -8.75 | -1.62 | 3.60 |
| 2026-05-19 | ALNY | -8.75 | -1.62 | 3.60 |
| 2026-05-20 | ALNY | -7.64 | -1.62 | 3.60 |
| 2026-05-21 | ALNY | -7.64 | -1.62 | 3.59 |
| 2026-05-22 | ALNY | -11.71 | -1.62 | 3.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.99
Avg. EPS Est. Current Quarter
2.17
Avg. EPS Est. Next Quarter
2.46
Insider Transactions
-11.71
Institutional Transactions
-1.62
Beta
0.29
Average Sales Estimate Current Quarter
1321
Average Sales Estimate Next Quarter
1480
Fair Value
294.26
Quality Score
93
Growth Score
64
Sentiment Score
92
Actual DrawDown %
40
Max Drawdown 5-Year %
-42.5
Target Price
441.58
P/E
70.68
Forward P/E
27.88
PEG
0.36
P/S
9.26
P/B
36.91
P/Free Cash Flow
61.92
EPS
4.21
Average EPS Est. Cur. Y
9.53
EPS Next Y. (Est.)
13.97
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
13.46
Relative Volume
0.6
Return on Equity vs Sector %
23
Return on Equity vs Industry %
38.6
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.32
EBIT Estimation
550.5
◆
ALNY
Healthcare
$297.45
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47
Range 1M
36.2%
Sup Dist
0.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
221.6%
EPS NY
42.3%
52W%
5.7%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+41.6% upside
Upside
+41.6%
Quality
93
MoS
-1%
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2500
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY
Latest News
—
Caricamento notizie per ALNY…
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading